Etonogestrel implants currently hold the leading market share. Their dominance is attributed to high clinical efficacy (over 99%), strong backing from NGOs, and wide acceptance within healthcare systems, particularly Merck & Co.’s Implanon NXT, which is favored for its three-year continuous protection and rapid restoration of fertility after removal.
Adoption is driven by the low maintenance requirements of implants, their near-perfect efficacy rate, and their cost-effectiveness as a long-term solution to prevent unintended pregnancies. Additionally, educational outreach campaigns and the shift in consumer preference toward convenient, "set-and-forget" reproductive health options are significant factors.
Asia-Pacific is projected to be the fastest-growing region. This growth is fueled by large populations, high fertility rates, and significant unmet contraceptive needs. Growth is further accelerated by government subsidies in countries like China, India, and Indonesia, alongside the emergence of affordable local manufacturers.
Hospitals represent the leading end-use segment because the insertion and removal of subdermal implants require specialized medical infrastructure and trained healthcare professionals. They serve as the primary points of care for both government-aided public health programs and private healthcare services.
In several conservative societies across Africa, the Middle East, and South Asia, adoption is hindered by myths, misconceptions regarding side effects, religious objections, and a lack of knowledge about the restoration of fertility. Addressing these requires culturally appropriate awareness campaigns and grassroots engagement.
In July 2024, Bayer AG announced an R&D program for levonorgestrel implants designed to last beyond five years. Such innovations aim to enhance long-term efficacy and reduce the frequency of clinical visits, catering to women seeking extended protection without the need for regular maintenance.
WHO prequalification, recently achieved by Shanghai Dahua Pharmaceutical Co., Ltd. for its levonorgestrel implant, is a landmark achievement. it allows companies to participate in large-scale procurement programs supported by international donors like the UNFPA, thereby stabilizing global supply chains and making implants more affordable in low-income regions.
The market features prominent pharmaceutical and healthcare companies, including Merck & Co., Bayer AG, Shanghai Dahua Pharmaceutical Co., Ltd., Anhui Zhongxing Pharmaceutical Co., Ltd., Gedeon Richter Plc., DKT International, and Cipla Limited.
Significant opportunities lie in the development of "Next-Gen Implants," which include the use of biodegradable materials that eliminate the need for surgical removal. Other opportunities include the expansion of public-private partnerships to improve accessibility in underserved areas and the use of digital health tools to improve contraceptive awareness.
